Abstract
We previously reported the results of a double-blind, placebo-controlled study of Filgrastim in patients with de novo AML undergoing induction and consolidation chemotherapy. The study demonstrated that Filgrastim was effective and well tolerated and had no impact on complete remission or survival. We now report follow-up data on these patients, assessing long-term effects with emphasis on prognostic indicators. After a median follow-up of 7 years, 434 (83%) patients were dead, 73 (14%) were alive, and 14 (3%) were lost to follow-up. The proportions of deaths were similar in the Filgrastim (83%) and placebo (84%) groups. No differences in median time to death (1.04 years Filgrastim, 1.13 years placebo; P=0.97) or median disease-free survival (0.86 years Filgrastim, 0.79 years placebo; P=0.52) were evident. Proportional hazard modeling identified age, performance status, and French-American-British subtype as independent predictors for survival (P<0.001, P=0.005, and P=0.036, respectively), whereas cytogenetic status was not (P=0.118). Filgrastim had no effect on overall survival in any of these subgroup analyses as none of the treatment comparisons were statistically significant. These findings indicate that Filgrastim can be effectively used to support patients with AML undergoing induction and consolidation chemotherapy without worsening long-term disease outcome.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Russell NH . Biology of acute leukemia. Lancet 1997; 349: 118–122.
Löwenberg B, Downing JR, Burnett A . Acute myeloid leukemia. N Engl J Med 1999; 341: 1051–1062.
Estey EH, Kantarjian H, Keating MJ . Therapy for acute myeloid leukemia. In: Hoffman R, Benz EJJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P (eds). Hematology: Basic Principles and Practice, 3rd edn. Churchill Livingstone: New York, NY, 2000, pp 1025–1042.
Büchner T, Hiddemann W, Wörmann B, Zuhlsdorf M, Rottman R, Innig G et al. Hematopoietic growth factors in acute myeloid leukemia: supportive and priming effects. Semin Oncol 1997; 24: 124–131.
Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325: 164–170.
Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A: 319–324.
Heil G, Hoelzer D, Sanz MA, Lechner K, Yin JAL, Papa G et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 1997; 90: 4710–4718.
Cancer Facts and Figures 2003. www.cancer.org. Accessed 11 March 2003.
Estey EH . Therapeutic options for acute myelogenous leukemia. Cancer 2001; 92: 1059–1073.
Hiddemann W, Wormann B, Reuter C, Schleyer E, Zuhlsdorf M, Bockmann A et al. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors. Semin Oncol 1994; 21 (6 Suppl 16): 33–38.
Schiffer CA . Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996; 88: 3675–3685.
Terpstra W, Löwenberg B . Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia 1997; 11: 315–327.
Rowe JM, Liesveld JL . Hematopoietic growth factors in acute leukemia. Leukemia 1997; 11: 328–341.
Bradstock K, Matthews J, Young G, Lowenthal R, Baxter H, Artur C et al. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukemia. Leukemia 2001; 15: 1331–1338.
Kalaycio M, Pohlman B, Elson P, Lichtin A, Hussein M, Tripp B et al. Chemotherapy for acute myelogenous leukemia in the elderly with cytarabine, mitoxantrone, and granulocyte-macrophage colony-stimulating factor. Am J Clin Oncol 2001; 42: 58–63.
Usuki K, Urabe K, Masaoka T, Ohno R, Mizoguchi H, Hamajima N et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Hematol 2002; 116: 103–112.
Bennett JM, Young ML, Andersen JW, Cassileth PA, Tallman MS . Long-term survival in acute myeloid leukemia. Cancer 1997; 80 (Suppl 11): 2205–2209.
Zittoun RA, Mandelli F, Willemze R, De Witte T, Labar B, Resegotti L et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995; 332: 217–223.
Harousseau J, Cahn J, Pignon B, Witz F, Milpied N, Delain M et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997; 90: 2978–2986.
Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paiatta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–1656.
Acknowledgements
The following hospitals and investigators participated in the International AML study group: Derriford Hospital, Plymouth, UK (A Prentice); Manchester Royal Infirmary, UK (JA Liu Yin); Royal London Hospital, UK (A Newland); Addenbrooke's Hospital, Cambridge, UK (R Marcus); Musgrove Park Hospital, Taunton, UK (S Johnson); Guys Hospital, London, UK (S Schey); John Radcliffe Hospital, Oxford, UK (T Littlewood and C Bunch); University of Frankfurt, Germany (D Hoelzer and A Ganser); University of Ulm, Germany (G Heil and H Heimpel); University of Freiburg, Germany (R Mertelsmann and A Lindemann); Johannes-Guttenberg University, Mainz, Germany (C Huber and K. Kolbe); Ospedali Riuniti, Bergamo, Italy (T Barbui); Ospedale Regionale, Bolzano, Italy (P Coser); Ospedale San Bortoli, Vicenza, Italy (R Battista and F Rodeghiero); Ospedale S Eugenio, Roma, Italy (G Papa and A Venditti); University Eppendorf, Hamburg, Germany (D Hossfeld); Stuyvenberg Ziekenhuis, Antwerpen, Belgium (P Zachée); Ospedale Nuovo San Gerardo, Monza, Italy (G Corneo and E Pogliani); Hospital La Fe, Valencia, Spain (M Sanz and G MartÃn); Hospital de la Princesa, Madrid, Spain (J Fernández-Rañada and J Tomás); University of Vienna, Austria (K Lechner and K Geissler); Belfast City Hospital, UK (TCM Morris); University of Gent, Belgium (L Noens); Centre Hospitalier Sart Tilman, Liège, Belgium (G Fillet); Instituto Portugues de Oncologia (A Parreira); University Hospital of Lund, Sweden (PG Nilsson); and the Australian Leukaemia Study Group: Peter McCallum Cancer Institute, Melbourne (J Bishop); Royal Adelaide Hospital (C Juttner and J Ho); Royal Prince Alfred Hospital, Sydney (D Joshua); Westmead Hospital, Sydney (K Bradstock); Alfred Hospital, Melbourne (J Szer); Royal Melbourne Hospital (J Szer).
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Sponsored by Amgen Ltd, Cambridge, UK and F Hoffmann-La Roche Ltd, Basel, Switzerland.
Presented at the 44th annual meeting of the American Society of Hematology, Philadelphia, PA, USA; December 6–10, 2002.
Rights and permissions
About this article
Cite this article
Heil, G., Hoelzer, D., Sanz, M. et al. Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia 20, 404–409 (2006). https://doi.org/10.1038/sj.leu.2404090
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404090